Margaret McCartney: Flibanserin for low sexual desire is not feminism
Author:
- Margaret McCartneyMMMargaret McCartney
Abstract
The UK Medicines and Healthcare Products Regulatory Agency will neither confirm nor deny it, but flibanserin is likely to be coming to British shores. Its maker, Sprout Pharmaceuticals, told me that it is “committed to working closely with other regulatory bodies outside the US . . . to bring to market a safe and effective treatment for the millions of women around the world affected by distressing low sexual desire.” The drug was licensed at the third attempt in the United States for the treatment of hypoactive sexual desire in premenopausal women.1 Ironically, a pressure group used the feminism argument to push for the US Food and Drug Administration’s approval on grounds of equality (men have their drugs; we want ours), when …Keywords
This publication has 5 references indexed in Scilit:
- Flibanserin for Low Sexual Desire in Women: A Molecule From Bench to Bed?EBioMedicine, 2015
- FDA committee recommends approval for "female Viagra"2015
- Hypoactive sexual desire in womenMenopause, 2013
- The history of ‘Female Sexual Dysfunction’ as a mental disorder in the 20th centuryCurrent Opinion in Psychiatry, 2010
- Sexual Dysfunction in the United StatesJAMA, 1999